Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda and SBRT in Advanced Pancreatic Cancer
NCT03716596Phase 1Terminated
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Oct 2018
- Primary completion
- Oct 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pembrolizumab in pancreatic cancer (PC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Overall Survival at 12 months. Started Oct 2018; status: terminated.
02
Drugs
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03716596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03716596.